133 related articles for article (PubMed ID: 14770081)
1. Bispecific single-chain diabody-mediated killing of endoglin-positive endothelial cells by cytotoxic T lymphocytes.
Korn T; Müller R; Kontermann RE
J Immunother; 2004; 27(2):99-106. PubMed ID: 14770081
[TBL] [Abstract][Full Text] [Related]
2. Targeting of adenovirus to endothelial cells by a bispecific single-chain diabody directed against the adenovirus fiber knob domain and human endoglin (CD105).
Nettelbeck DM; Miller DW; Jérôme V; Zuzarte M; Watkins SJ; Hawkins RE; Müller R; Kontermann RE
Mol Ther; 2001 Jun; 3(6):882-91. PubMed ID: 11407902
[TBL] [Abstract][Full Text] [Related]
3. Bispecific single-chain diabody-immunoliposomes targeting endoglin (CD105) and fibroblast activation protein (FAP) simultaneously.
Rabenhold M; Steiniger F; Fahr A; Kontermann RE; Rüger R
J Control Release; 2015 Mar; 201():56-67. PubMed ID: 25617725
[TBL] [Abstract][Full Text] [Related]
4. A recombinant, fully human, bispecific antibody neutralizes the biological activities mediated by both vascular endothelial growth factor receptors 2 and 3.
Jimenez X; Lu D; Brennan L; Persaud K; Liu M; Miao H; Witte L; Zhu Z
Mol Cancer Ther; 2005 Mar; 4(3):427-34. PubMed ID: 15767551
[TBL] [Abstract][Full Text] [Related]
5. Effective targeting of prostate cancer by lymphocytes redirected by a PSMA × CD3 bispecific single-chain diabody.
Fortmüller K; Alt K; Gierschner D; Wolf P; Baum V; Freudenberg N; Wetterauer U; Elsässer-Beile U; Bühler P
Prostate; 2011 May; 71(6):588-96. PubMed ID: 20945402
[TBL] [Abstract][Full Text] [Related]
6. Targeting of immunoliposomes to endothelial cells using a single-chain Fv fragment directed against human endoglin (CD105).
Völkel T; Hölig P; Merdan T; Müller R; Kontermann RE
Biochim Biophys Acta; 2004 May; 1663(1-2):158-66. PubMed ID: 15157618
[TBL] [Abstract][Full Text] [Related]
7. Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct.
Hoffmann P; Hofmeister R; Brischwein K; Brandl C; Crommer S; Bargou R; Itin C; Prang N; Baeuerle PA
Int J Cancer; 2005 May; 115(1):98-104. PubMed ID: 15688411
[TBL] [Abstract][Full Text] [Related]
8. Human endoglin-CD3 bispecific T cell engager antibody induces anti-tumor effect
Zhong L; Shi W; Gan L; Liu X; Huo Y; Wu P; Zhang Z; Wu T; Peng H; Huang Y; Zhao Y; Yuan Y; Deng Z; Tang H
Theranostics; 2021; 11(13):6393-6406. PubMed ID: 33995664
[No Abstract] [Full Text] [Related]
9. Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy.
Burrows FJ; Derbyshire EJ; Tazzari PL; Amlot P; Gazdar AF; King SW; Letarte M; Vitetta ES; Thorpe PE
Clin Cancer Res; 1995 Dec; 1(12):1623-34. PubMed ID: 9815965
[TBL] [Abstract][Full Text] [Related]
10. Design, selection and optimization of an anti-TRAIL-R2/anti-CD3 bispecific antibody able to educate T cells to recognize and destroy cancer cells.
Satta A; Mezzanzanica D; Caroli F; Frigerio B; Di Nicola M; Kontermann RE; Iacovelli F; Desideri A; Anichini A; Canevari S; Gianni AM; Figini M
MAbs; 2018 Oct; 10(7):1084-1097. PubMed ID: 29993310
[TBL] [Abstract][Full Text] [Related]
11. CD3X anti-nitrophenyl bispecific diabodies: universal immunotherapeutic tools for retargeting T cells to tumors.
Manzke O; Fitzgerald KJ; Holliger P; Klock J; Span M; Fleischmann B; Hescheler J; Qinghua L; Johnson KS; Diehl V; Hoogenboom HR; Bohlen H
Int J Cancer; 1999 Aug; 82(5):700-8. PubMed ID: 10417768
[TBL] [Abstract][Full Text] [Related]
12. A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells.
Bühler P; Wolf P; Gierschner D; Schaber I; Katzenwadel A; Schultze-Seemann W; Wetterauer U; Tacke M; Swamy M; Schamel WW; Elsässer-Beile U
Cancer Immunol Immunother; 2008 Jan; 57(1):43-52. PubMed ID: 17579857
[TBL] [Abstract][Full Text] [Related]
13. Specific killing of lymphoma cells by cytotoxic T-cells mediated by a bispecific diabody.
Holliger P; Brissinck J; Williams RL; Thielemans K; Winter G
Protein Eng; 1996 Mar; 9(3):299-305. PubMed ID: 8736497
[TBL] [Abstract][Full Text] [Related]
14. Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro.
Bellone S; Black J; English DP; Schwab CL; Lopez S; Cocco E; Bonazzoli E; Predolini F; Ferrari F; Ratner E; Silasi DA; Azodi M; Schwartz PE; Santin AD
Am J Obstet Gynecol; 2016 Jan; 214(1):99.e1-8. PubMed ID: 26272866
[TBL] [Abstract][Full Text] [Related]
15. Lack of specificity of endoglin expression for tumor blood vessels.
Balza E; Castellani P; Zijlstra A; Neri D; Zardi L; Siri A
Int J Cancer; 2001 Nov; 94(4):579-85. PubMed ID: 11745447
[TBL] [Abstract][Full Text] [Related]
16. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309
[TBL] [Abstract][Full Text] [Related]
17. Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin.
Müller D; Karle A; Meissburger B; Höfig I; Stork R; Kontermann RE
J Biol Chem; 2007 Apr; 282(17):12650-60. PubMed ID: 17347147
[TBL] [Abstract][Full Text] [Related]
18. Construction and characterization of a bispecific diabody for retargeting T cells to human carcinomas.
Helfrich W; Kroesen BJ; Roovers RC; Westers L; Molema G; Hoogenboom HR; de Leij L
Int J Cancer; 1998 Apr; 76(2):232-9. PubMed ID: 9537586
[TBL] [Abstract][Full Text] [Related]
19. Efficient inhibition of human B-cell lymphoma xenografts with an anti-CD20 x anti-CD3 bispecific diabody.
Xiong D; Xu Y; Liu H; Peng H; Shao X; Lai Z; Fan D; Yang M; Han J; Xie Y; Yang C; Zhu Z
Cancer Lett; 2002 Mar; 177(1):29-39. PubMed ID: 11809528
[TBL] [Abstract][Full Text] [Related]
20. Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin.
Seon BK; Matsuno F; Haruta Y; Kondo M; Barcos M
Clin Cancer Res; 1997 Jul; 3(7):1031-44. PubMed ID: 9815781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]